Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pfizer Inc

NYSE: PFE · Life Sciences · 3 alerts · CIK 78003

Share price
$28.86Close, Nov 16
Market cap
$164B
Shares outstanding
5.7BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pfizer Inc filings on SEC EDGAR ↗

8:20 AM ET 10-Q
Financial Results

Pfizer Q3 2026 Results: Net Income $3.24B, Down 8.4% YoY

For the three months ended September 27, 2026, Pfizer reported total revenues of $16.58 billion, a slight decrease from $16.65 billion in the prior year period. Net income attributable to common shareholders for the quarter was $3.24 billion ($0.56 per diluted share), down from $3.54 billion ($0.62 per diluted share) in the same period of 2025.

Key figure
Net income $3.24B · -8.4% YoY
8:08 AM ET 8-K
Financial Results

Pfizer Financial Results

Pfizer reported Q3 2026 revenues of $16.6 billion, with 32% operational growth from launched and acquired products. The company raised its full-year 2026 revenue guidance to $62.0-$64.0 billion and appointed Cecile Guegan as its new Chief Financial Officer.

Term
Q3 2026

“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”

Dr. Albert Bourla, Chairman and CEO of Pfizer

“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”

Cecile Guegan, CFO and EVP of Pfizer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.